

John V Heymach

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1949492/john-v-heykach-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

532
papers

36,214
citations

88
h-index

179
g-index

768
ext. papers

45,420
ext. citations

7.3
avg, IF

7.98
L-index

#	Paper	IF	Citations
532	Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer.. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022 ,	1.5	3
531	Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.. <i>Cancer Treatment and Research Communications</i> , 2022 , 30, 100514	2	1
530	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.. <i>Lung Cancer</i> , 2022 , 164, 69-75	5.9	0
529	In Response.. <i>Journal of Thoracic Oncology</i> , 2022 , 17, e39	8.9	
528	AXL targeting restores PD-1 blockade sensitivity of mutant NSCLC through expansion of TCF1 CD8 T _H cells.. <i>Cell Reports Medicine</i> , 2022 , 3, 100554	18	4
527	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.. <i>Nature Communications</i> , 2022 , 13, 1797	17.4	0
526	ANTIangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.. <i>European Journal of Cancer</i> , 2022 , 166, 112-125	7.5	0
525	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 172	12.8	
524	Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR).. <i>Annals of Surgical Oncology</i> , 2022 ,	3.1	
523	/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. <i>Clinical Cancer Research</i> , 2021 , 27, 1720-1733	12.9	9
522	Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2021 , 14, 313-324	3.2	9
521	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2021 ,	8.9	14
520	Pozotinib in Non-Small-Cell Lung Cancer Harboring Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101323	2.2	11
519	Tepotinib Efficacy and Safety in Patients with Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. <i>Clinical Cancer Research</i> , 2021 ,	12.9	5
518	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. <i>Nature Communications</i> , 2021 , 12, 6655	17.4	1
517	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With or Alterations. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100237	1.4	0
516	Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. <i>Molecular Cancer Research</i> , 2021 ,	6.6	2

515	Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology 2021 ,		15
514	Single-Cell Expression Landscape of SARS-CoV-2 Receptor and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4
513	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. <i>Cancer Cell</i> , 2021 , 39, 346-360.e7	24.3	107
512	Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. <i>Immunity</i> , 2021 , 54, 586-602.e8	32.3	16
511	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021 , 5, 21	9.8	2
510	Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. <i>Lung Cancer</i> , 2021 , 154, 76-83	5.9	5
509	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 583-600	8.9	18
508	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 601-609	8.9	11
507	Driver mutations to predict for poorer outcomes in non-small cell lung cancer patients treated with concurrent chemoradiation and consolidation durvalumab.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8528-8528	2.2	3
506	ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. <i>Nature Cancer</i> , 2021 , 2, 503-514	15.4	18
505	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. <i>Cancer Discovery</i> , 2021 , 11, 2506-2523	24.4	15
504	Prognostic factors in RET dependent cancers treated with RET inhibitors in early phase clinical trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3117-3117	2.2	
503	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. <i>Nature Communications</i> , 2021 , 12, 2722	17.4	16
502	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1821-1839	8.9	8
501	Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 161, 1497-1504.e2	1.5	14
500	Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2021 , 22, e415-e424	4.9	5
499	Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. <i>Clinical Lung Cancer</i> , 2021 , 22, e451-e465	4.9	11
498	Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 205-215	8.9	36

497	Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 467-475	35.1	72
496	AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. <i>Molecular Cancer Research</i> , 2021 , 19, 485-497	6.6	9
495	A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 477-489	6.1	4
494	Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 269-277	8.9	3
493	Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. <i>Chest</i> , 2021 , 159, 1256-1264	5.3	5
492	Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. <i>Clinical Cancer Research</i> , 2021 , 27, 852-864	12.9	12
491	Altered Regulation of HIF-1 β in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 439-451	8.9	11
490	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 127-139	8.9	14
489	Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. <i>European Journal of Cardio-thoracic Surgery</i> , 2021 , 59, 100-108	3	5
488	Current and future treatment options for exon 14 skipping alterations in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 1758835921992976	5.4	9
487	CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions: A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS449-TPS449	2.2	1
486	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. <i>Nature Communications</i> , 2021 , 12, 687	17.4	9
485	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021 , 27, 504-514	50.5	105
484	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2051-2064	8.9	1
483	Radiological tumor classification across imaging modality and histology. <i>Nature Machine Intelligence</i> , 2021 , 3, 787-798	22.5	9
482	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021 , 12, 5045	17.4	6
481	Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	3
480	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer 2021 , 9,		13

479	Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1289-1297	8.9	6
478	ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC. <i>Cancer Cell</i> , 2021 , 39, 1178-1180	24.3	2
477	Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021 , 597, 732-737	30.4	30
476	Pozotinib for Patients With Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101113	2.2	9
475	Inhibition of nonsense-mediated decay rescues p53 β isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. <i>Journal of Biological Chemistry</i> , 2021 , 297, 101163	5.4	5
474	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. <i>Radiotherapy and Oncology</i> , 2021 , 162, 60-67	5.3	11
473	Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. <i>Lancet Oncology</i> , 2021 , 22, 1448-1457	21.7	26
472	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1965-1976	7.4	1
471	Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, S1-S11	7.3	0
470	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. <i>Nature Communications</i> , 2021 , 12, 7081	17.4	1
469	Prolonged Central Nervous System Response in a Patient With Mutant NSCLC Treated With First-Line Pozotinib. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100081	1.4	0
468	Multimomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. <i>Genome Biology</i> , 2020 , 21, 271	18.3	13
467	Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 231-235	2.7	11
466	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort 2020 , 8,		13
465	Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020 , 383, 931-943	59.2	201
464	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1611-1623	8.9	16
463	An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis. <i>Neoplasia</i> , 2020 , 22, 294-310	6.4	5
462	What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. <i>JCO Oncology Practice</i> , 2020 , 16, e1151-e1160	2.3	1

461	A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. <i>Oncologist</i> , 2020 , 25, e1457-e1463	5.1	4
460	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. <i>Lung Cancer</i> , 2020 , 146, 303-309	5.9	2
459	Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. <i>Journal of Thoracic Disease</i> , 2020 , 12, 1952-1959	2.6	4
458	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 709-740	8.9	77
457	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 777-791	8.9	39
456	Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 107, 261-269	4	3
455	Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. <i>BJU International</i> , 2020 , 125, 739-746	5.6	7
454	Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. <i>Nature Cancer</i> , 2020 , 1, 176-183	15.4	71
453	Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. <i>BMC Cancer</i> , 2020 , 20, 83	4.8	7
452	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3525-3536	12.9	9
451	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. <i>Clinical Lung Cancer</i> , 2020 , 21, 341-348	4.9	27
450	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 892-901	12.9	34
449	I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9035-9035	2.2	3
448	BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9624-9624	2.2	2
447	KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. <i>American Journal of Cancer Research</i> , 2020 , 10, 4464-4475	4.4	3
446	Outcomes to first-line pembrolizumab in patients with PD-L1-high (50%) non-small-cell lung cancer and a poor performance status.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9568-9568	2.2	
445	LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. <i>Annals of Thoracic Surgery</i> , 2020 , 110, 1131-1138	2.7	4
444	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1449-1459	8.9	49

443	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020 , 11, 603	17.4	67
442	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. <i>Nature Cancer</i> , 2020 , 1, 423-436	15.4	88
441	Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 106, 349-357	4	15
440	Patterns of protein expression in human head and neck cancer cell lines differ after proton vs photon radiotherapy. <i>Head and Neck</i> , 2020 , 42, 289-301	4.2	7
439	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 2908-2920	12.8	12
438	Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. <i>Journal of NeuroImmune Pharmacology</i> , 2020 , 15, 27-36	6.9	15
437	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. <i>Oncogene</i> , 2020 , 39, 1846-1859	9.2	15
436	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 248-257	8.9	40
435	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 149, 33-40	5.9	2
434	Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1919-1927	8.9	20
433	Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial 2020 , 8,		46
432	Outcomes to first-line pembrolizumab in patients with PD-L1-high (50%) non-small cell lung cancer and a poor performance status 2020 , 8,		15
431	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. <i>ESMO Open</i> , 2020 , 5, e000799	6	15
430	New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020 , 25, 822-825	5.7	5
429	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	34
428	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. <i>Clinical Cancer Research</i> , 2020 , 26, 5477-5486	12.9	12
427	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020 , 109, 358-366	2.7	2
426	Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 266-273	8.9	25

425	Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, 37-46.e7	4.9	26
424	F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 1519-1534	7.4	11
423	Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. <i>Clinical Lung Cancer</i> , 2020 , 21, 384-388	4.8	5
422	A general statistic to test an optimally weighted combination of common and/or rare variants. <i>Genetic Epidemiology</i> , 2019 , 43, 966-979	2.6	2
421	Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy 2019 , 7, 237		44
420	Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 2152-2163	8.9	48
419	Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. <i>Molecular Cell</i> , 2019 , 76, 838-851.e5	17.6	51
418	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019 , 36, 444-457.e7	24.3	69
417	An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. <i>Nature Cell Biology</i> , 2019 , 21, 203-213	23.4	19
416	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1558-1565	2.2	445
415	Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, e187-e197	7.1	17
414	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1021-1031	8.9	46
413	LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in -Mutant Lung Adenocarcinoma. <i>Cancer Research</i> , 2019 , 79, 3251-3267	10.1	103
412	Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 742-750	10.2	12
411	Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019 , 20, e480-e488	4.9	1
410	Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. <i>EBioMedicine</i> , 2019 , 42, 296-303	8.8	8
409	Improved Overall Survival with Local Consolidative Therapy in Oligometastatic Non-Small Cell Lung Cancer: Results from a Cohort of 194 Patients with Synchronous Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 229	4	2
408	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. <i>Nature Reviews Cancer</i> , 2019 , 19, 289-297	31.3	304

407	Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. <i>Modern Pathology</i> , 2019 , 32, 1053-1064	9.8	27
406	A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 372-379	9.7	52
405	Powerful statistical method to detect disease-associated genes using publicly available genome-wide association studies summary data. <i>Genetic Epidemiology</i> , 2019 , 43, 941-951	2.6	5
404	Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2019 , 19, 495-509	31.3	250
403	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. <i>Nature Communications</i> , 2019 , 10, 2978	17.4	43
402	Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. <i>Seminars in Oncology</i> , 2019 , 46, 145-154	5.5	9
401	Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. <i>Cancer</i> , 2019 , 125, 3738-3748	6.4	13
400	miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer. <i>Neoplasia</i> , 2019 , 21, 849-862	6.4	26
399	Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1912-1923	8.9	41
398	Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. <i>Nature Communications</i> , 2019 , 10, 5076	17.4	17
397	Abstract 2215: SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer 2019 ,		3
396	Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 102-102	2.2	56
395	Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6009-6009	2.2	5
394	Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8504-8504	2.2	80
393	Tracking circulating cell-free tumor DNA in gastric cancer to detect early disease recurrence.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14571-e14571	2.2	
392	Distinct resistant mechanism and genomic evolution during TKI treatment in non-small cell lung cancer patients with or without acquired T790M mutation.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20603-e20603	2.2	
391	Pathogenic germline mutation profile in Chinese lung cancers and related-driver mutation pattern.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13003-e13003	2.2	
390	cfDNA analysis to reveal association of genomic features with chemotherapy response and survival in patients with pulmonary large-cell neuroendocrine carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14555-e14555	2.2	

389	Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14047-e14047	2.2	0
388	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2019 , 9, 646-661	24.4	288
387	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. <i>Cancer Discovery</i> , 2019 , 9, 628-645	24.4	124
386	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer 2019 , 7, 351		18
385	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. <i>Cancer Immunology Research</i> , 2019 , 7, 1903-1909	12.5	44
384	LCE: an open web portal to explore gene expression and clinical associations in lung cancer. <i>Oncogene</i> , 2019 , 38, 2551-2564	9.2	45
383	Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. <i>Cancer Research</i> , 2019 , 79, 125-132	10.1	31
382	Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1. <i>Journal of Molecular Medicine</i> , 2019 , 97, 49-61	5.5	25
381	Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. <i>Oncologist</i> , 2019 , 24, 772-782	5.7	19
380	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019 , 120, 340-345	8.7	17
379	Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. <i>Clinical Cancer Research</i> , 2019 , 25, 346-357	12.9	7
378	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. <i>Clinical Lung Cancer</i> , 2019 , 20, 30-36.e3	4.9	19
377	Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 150-157	12.9	7
376	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2019 , 20, 43-47	4.9	32
375	Polya tree priors and their estimation with multi-group data. <i>Statistical Papers</i> , 2019 , 60, 849-875	1	1
374	Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease. <i>Translational Lung Cancer Research</i> , 2019 , 8, 97-106	4.4	20
373	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. <i>Lung Cancer</i> , 2018 , 120, 137-141	5.9	22
372	Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. <i>Nature Medicine</i> , 2018 , 24, 638-646	50.5	213

371	Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. <i>Cell</i> , 2018 , 173, 864-878.e29	56.2	58
370	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. <i>Cell Metabolism</i> , 2018 , 27, 977-987.e4	24.6	241
369	Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. <i>Oncogene</i> , 2018 , 37, 3686-3697	9.2	28
368	Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. <i>Cancer</i> , 2018 , 124, 2355-2364	6.4	7
367	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. <i>Modern Pathology</i> , 2018 , 31, 947-955	9.8	35
366	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 246-257	8.9	11
365	A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. <i>Annals of Oncology</i> , 2018 , 29, 1561-1568	10.3	44
364	Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018 , 105, 1621-1626	2.7	4
363	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 779-791	8.9	39
362	Reply to Lambros et al. <i>Modern Pathology</i> , 2018 , 31, 541-542	9.8	
361	Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 46-52	2.7	2
360	RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 341-350	12.9	25
359	Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. <i>Modern Pathology</i> , 2018 , 31, 307-312	9.8	17
358	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. <i>Nature Communications</i> , 2018 , 9, 3114	17.4	73
357	De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer. <i>FASEB Journal</i> , 2018 , 32, fj201800204	0.9	24
356	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches 2018 , 6, 48		76
355	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. <i>Cancer Discovery</i> , 2018 , 8, 1156-1175	24.4	195
354	Profiles of brain metastases: Prioritization of therapeutic targets. <i>International Journal of Cancer</i> , 2018 , 143, 3019-3026	7.5	17

353	Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer 2018 ,		15
352	Characterization of KEAP1-NRF2 genomic alterations across diverse tumor types: Co-occurring alterations, survival outcomes, and implications for targeting cancer metabolism.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2558-2558	2.2	1
351	Outcomes of patients with gene fusion driven cancers treated on early phase clinical trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2590-2590	2.2	1
350	Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3056-3056	2.2	6
349	SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemo-naïve patients with malignant pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8514-8514	2.2	6
348	Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9028-9028	2.2	4
347	Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9052-9052	2.2	22
346	An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS3120-TPS3120	2.2	4
345	Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS8580-TPS8580	2.2	4
344	EA5142 adjuvant nivolumab in resected lung cancers (ANVIL).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS8581-TPS8581	2.2	6
343	Association of the T-cell receptor landscape with survival in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 140-140	2.2	2
342	A preclinical study of tumor-infiltrating lymphocytes in NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 161-161	2.2	2
341	Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 33258-33270	3.3	4
340	FAK as a Target for Therapy in Head and Neck Cancer. <i>Current Cancer Research</i> , 2018 , 469-490	0.2	0
339	Abstract 213: Exome sequencing of paired primary and relapsed small cell lung cancers reveals increased copy number aberration complexity to be associated with disease relapse 2018 ,		2
338	Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. <i>Cancer</i> , 2018 , 124, 1061-1069	6.4	8
337	Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018 , 105, 418-424	2.7	14
336	Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. <i>Cancer Research</i> , 2018 , 78, 781-797	10.1	28

335	BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 600-607.	9	15
334	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1020-1044	2.2	83
333	Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1813-1822	2.2	156
332	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2386-2394	2.2	162
331	OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2018 , 13, S323-S324	8.9	62
330	MA06.02 Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer: Genomic and Immune Profiling Updates from Project ICON. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S375	8.9	2
329	MA19.10 Impact of STK11/LKB1 Genomic Alterations on Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S424-S425	8.9	2
328	P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S733-S734	8.9	2
327	Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. <i>Journal of Translational Medicine</i> , 2018 , 16, 328	8.5	7
326	Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 1681-1691	4	21
325	Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. <i>JAMA Network Open</i> , 2018 , 1, e181390	10.4	27
324	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in -Mutant NSCLC. <i>Clinical Cancer Research</i> , 2018 , 24, 6195-6203	12.9	178
323	eIF2 α subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. <i>Cancer Science</i> , 2018 , 109, 1843-1852	6.9	13
322	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018 , 8, 822-835	24.4	648
321	Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. <i>Clinical Cancer Research</i> , 2018 , 24, 5735-5743	12.9	34
320	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1341-1367	2.2	75
319	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline Mutations and Selected Sporadic Cancers. <i>Cancer Discovery</i> , 2017 , 7, 620-629	24.4	232
318	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. <i>Cancer Immunology Research</i> , 2017 , 5, 319-329	12.5	9

317	Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 983-992	8.9	41
316	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. <i>Cancer Cell</i> , 2017 , 31, 225-239	23.9	139
315	Consolidative local therapy in oligometastatic patients - Authors'Reply. <i>Lancet Oncology</i> , 2017 , 18, e62	21.7	
314	Tumor Angiogenesis 2017 , 1-32		
313	Monitoring seasonal influenza epidemics by using internet search data with an ensemble penalized regression model. <i>Scientific Reports</i> , 2017 , 7, 46469	4.9	18
312	Tumor-Infiltrating Lymphocytes and Overall Survival in Surgically Resected Stage II and III Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 223	4	4
311	Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy. <i>Carcinogenesis</i> , 2017 , 38, 419-424	4.6	7
310	CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. <i>Cancer Research</i> , 2017 , 77, 3870-3884	19.1	107
309	Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2713-2722	12.9	66
308	Plasma Riboflavin Level is Associated with Risk, Relapse, and Survival of Esophageal Squamous Cell Carcinoma. <i>Nutrition and Cancer</i> , 2017 , 69, 21-28	2.8	10
307	Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. <i>Journal of Clinical Oncology</i> , 2017 , 35, 352-360	2.2	104
306	Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	17
305	MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk. <i>Annals of Oncology</i> , 2017 , 28, 1124-1129	10.3	21
304	Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. <i>Cell Reports</i> , 2017 , 19, 1669-1684	10.6	55
303	CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. <i>Nature</i> , 2017 , 546, 168-172	50.4	136
302	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5648-5656	12.9	38
301	Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer. <i>Cancer Science</i> , 2017 , 108, 732-743	6.9	11
300	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5489-5501	12.9	41

299	The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1280-1287	8.9	38
298	MA04.07 Impact of Major Co-Mutations on the Immune Contexture and Response of KRAS-Mutant Lung Adenocarcinoma to Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S361-S362	8.9	7
297	OA20.06 Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer - The ICON Project. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S324-S325	8.9	3
296	MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S406-S407	8.9	10
295	P1.07-024 EGFR Mutations in Small Cell Lung Cancer (SCLC): Genetic Heterogeneity and Prognostic Impact. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S710-S711	8.9	2
294	7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. <i>Cancer</i> , 2017 , 123, 3031-3039	6.4	87
293	Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 900-907	4	24
292	Phase 1 Study of Pembrolizumab and Stereotactic or Hypofractionated Radiation for Metastatic Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, S160-S161	4	4
291	Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. <i>Cancer Research</i> , 2017 , 77, 6119-6130	10.1	56
290	Predictive biomarkers for response of esophageal cancer to chemo(radio)therapy: A systematic review and meta-analysis. <i>Surgical Oncology</i> , 2017 , 26, 460-472	2.5	16
289	PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions. <i>Cancer Prevention Research</i> , 2017 , 10, 684-693	3.2	33
288	Artesunate suppresses the viability and mobility of prostate cancer cells through UCA1, the sponge of miR-184. <i>Oncotarget</i> , 2017 , 8, 18260-18270	3.3	38
287	Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. <i>Oncotarget</i> , 2017 , 8, 28575-28587	3.3	104
286	Updated incidence rates and risk factors of esophageal cancer in Nantao Island, a coastal high-risk area in southern China. <i>Ecological Management and Restoration</i> , 2017 , 30, 1-7	3	9
285	Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. <i>JAMA Oncology</i> , 2017 , 3, e172032	13.4	90
284	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017 , 7, 1088-1097	24.4	105
283	Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer. <i>Journal of the American Society for Mass Spectrometry</i> , 2017 , 28, 2078-2089	3.5	11
282	Preliminary Results of a Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1536	8.9	5

281	Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. <i>ESMO Open</i> , 2017 , 2, e000102	6	7
280	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017 , 112, 90-95	5.9	128
279	MA 01.03 The Potential of ctDNA Sequencing in Disease Monitoring and Depicting Genomic Evolution of Small-Cell Lung Cancer Under Therapy. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1800	8.9	2
278	MA 05.02 STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1815	8.9	3
277	Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy. <i>Lung Cancer</i> , 2017 , 114, 70-78	5.9	8
276	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Eblockers. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	62
275	Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 6239-6253	12.9	56
274	Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2017 , 117, 478-484	8.7	12
273	Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	31
272	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. <i>Molecular Cancer Research</i> , 2017 , 15, 45-58	6.6	55
271	Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 770-777	4	11
270	Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 141-148	4.9	9
269	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 1388-1396	12.9	199
268	CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS. <i>Neuro-Oncology</i> , 2017 , 19, vi40-vi41	1	78
267	OA 12.01 The Preclinical and Clinical Activity of Pozotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1776	8.9	8
266	Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 1315	4	16
265	Germline and Somatic Smoothed Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-10	3.6	2
264	Immune profiling of oral pre-malignant lesions (OPLs): An Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1545-1545	2.2	6

263	DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3064-3064	2.2	7
262	Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6017-6017	2.2	3
261	Association of activating NOTCH1 mutations in adenoid cystic carcinoma with shorter progression-free survival to systemic therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6089-6089	2.2	1
260	Intratumor heterogeneity of stage IA lung adenocarcinoma by multiregion whole exome sequencing and association with survival.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8545-8545	2.2	1
259	Histology determination of lung cancers: A report on genomic profiling of lung cancer of mixing histology.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8570-8570	2.2	2
258	STK11/LKB1 co-mutations to predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9016-9016	2.2	13
257	Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9083-9083	2.2	1
256	Immunogenomic profiling of non-small cell lung cancer: The ICON project.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20034-e20034	2.2	1
255	EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS8575-TPS8575	2.2	5
254	DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. <i>Oncotarget</i> , 2017 , 8, 21994-22003	3.3	2
253	Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. <i>Oncotarget</i> , 2017 , 8, 73419-73432	3.3	48
252	Comprehensive molecular and immune profiling of non-small cell lung cancer and matched distant metastases to suggest distinct molecular mechanisms underlying metastasis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8541-8541	2.2	
251	Multiregion gene-expression profiling to reveal heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20077-e20077	2.2	
250	Genomic and transcriptomic profiling of localized sarcomatoid carcinoma of the lung to reveal association between immune activation and a lower risk of recurrence.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20058-e20058	2.2	
249	Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 8538-8538	2.2	
248	Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS3096-TPS3096	2.2	2
247	Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20654-e20654	2.2	
246	Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11609-11609	2.2	

245	TCR repertoire sequencing of 254 resected non-small cell lung cancers to reveal TCR clonality in normal tissues compared to tumor tissues.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11500-11500	2.2	
244	Abstract 2061: Non-covalent EGFR T790M targeting TKIs inhibit AZD9291 resistant EGFR C797S mutants 2017 ,		2
243	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2016 , 22, 609-20	12.9	254
242	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. <i>Clinical Cancer Research</i> , 2016 , 22, 1103-10	12.9	282
241	MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. <i>Genome Biology</i> , 2016 , 17, 178	18.3	120
240	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. <i>Lancet Oncology, The</i> , 2016 , 17, 1672-1682	21.7	548
239	Genomic heterogeneity of multiple synchronous lung cancer. <i>Nature Communications</i> , 2016 , 7, 13200	17.4	85
238	Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S. <i>Scientific Reports</i> , 2016 , 6, 26760	4.9	10
237	Selecting Reliable mRNA Expression Measurements Across Platforms Improves Downstream Analysis. <i>Cancer Informatics</i> , 2016 , 15, 81-9	2.4	1
236	Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 6278-6289	12.9	96
235	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. <i>Clinical Cancer Research</i> , 2016 , 22, 1940-50	12.9	11
234	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016 , 76, 999-1008	10.1	297
233	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 3630-42	12.9	246
232	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 453-74	8.9	106
231	Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 209-16	13.4	89
230	Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1674-1686	12.9	32
229	Abstract CT027: A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1) 2016 ,		2
228	Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8500-8500	2.2	23

227	A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8512-8512	2.2	14
226	Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9004-9004	2.2	4
225	Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9069-9069 ⁹	3.3	9
224	Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9073-9073	2.2	5
223	ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3107-TPS3107 ¹⁷	2.2	17
222	Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016 , 11, e0152584	3.7	52
221	Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. <i>Oncotarget</i> , 2016 , 7, 47998-48010	3.3	13
220	Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. <i>Oncotarget</i> , 2016 , 7, 565-79 ³	3.3	25
219	Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. <i>Oncotarget</i> , 2016 , 7, 3548-58	3.3	89
218	Clinical utilization of a CLIA-certified cell-free DNA (cfDNA) blood test for identification of targetable molecular alterations in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23064-e23064	2.2	
217	Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2546-2546 ²³	2.2	23
216	Preliminary analysis of genomic profiling of small cell lung cancer in Chinese population revealed frequent PIK3CA hotspot mutations.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20089-e20089	2.2	
215	Proteomic and mRNA expression analysis identifies PDL-1 expression as a marker of treatment failure in head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6042-6042	2.2	
214	Intra-tumor heterogeneity of T cell receptor repertoire in lung cancers and its association with tumor genomic profile.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8539-8539	2.2	0
213	The CDK4/6 inhibitor G1T28 to protect immune cells and fibroblasts from chemotherapy and radiation-induced toxicity in vitro and to maintain efficacy of chemotherapy in SCLC Rb-deficient cells.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20099-e20099	2.2	
212	Reprogramming of cell signaling in response to MEK inhibition in non-small cell cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23222-e23222	2.2	
211	Upregulation of lactate dehydrogenase a by 14-3-3 leads to increased glycolysis critical for breast cancer initiation and progression. <i>Oncotarget</i> , 2016 , 7, 35270-83	3.3	22
210	Single nucleotide polymorphism rs13042395 in the SLC52A3 gene as a biomarker for regional lymph node metastasis and relapse-free survival of esophageal squamous cell carcinoma patients. <i>BMC Cancer</i> , 2016 , 16, 560	4.8	9

209	MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. <i>Current Opinion in Oncology</i> , 2016 , 28, 195-200	4.2	22
208	Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. <i>Cancer</i> , 2016 , 122, 534-45	6.4	45
207	Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016 , 38, 439-47	4.2	18
206	Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2016 , 17, e5-11	4.9	27
205	Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 5851-5863	12.9	45
204	191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 5133-5140	8.9	32
203	Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1357-1362	8.9	25
202	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 4643-50	12.9	44
201	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3638-3647	2.2	108
200	PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. <i>Cancer Biology and Therapy</i> , 2015 , 16, 402-11	4.6	31
199	Can the Lung Cancer Pie Be Divided into Angiogenic Slices?. <i>Clinical Cancer Research</i> , 2015 , 21, 5188-90	12.9	1
198	Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. <i>Cancer Discovery</i> , 2015 , 5, 860-77	24.4	476
197	Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. <i>British Journal of Cancer</i> , 2015 , 112, 1199-205	8.7	34
196	Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. <i>Lung Cancer</i> , 2015 , 89, 76-9	5.9	48
195	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. <i>Clinical Cancer Research</i> , 2015 , 21, 3480-91	12.9	36
194	Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 682-90	8.9	95
193	Predictive biomarkers in precision medicine and drug development against lung cancer. <i>Chinese Journal of Cancer</i> , 2015 , 34, 295-309		29
192	Strategies for combining immunotherapy with radiation for anticancer therapy. <i>Immunotherapy</i> , 2015 , 7, 967-980	3.8	64

191	The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression. <i>Oncolmmunology</i> , 2015 , 4, e1002731	7.2	19
190	SABR vs surgery for NSCLC in the media. <i>Lancet Oncology, The</i> , 2015 , 16, e422	21.7	6
189	Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. <i>Cancer</i> , 2015 , 121, 2968-75	6.4	17
188	8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition. <i>PLoS ONE</i> , 2015 , 10, e0135962	3.7	10
187	drexplore: A tool to explore dose-response relationships and drug-drug interactions. <i>Bioinformatics</i> , 2015 , 31, 1692-4	7.2	19
186	Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2015 , 26, 1476-80	10.3	57
185	In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. <i>Molecular Therapy - Nucleic Acids</i> , 2015 , 4, e270	10.7	47
184	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. <i>Cancer Letters</i> , 2015 , 357, 179-185	9.9	68
183	Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. <i>British Journal of Cancer</i> , 2015 , 112, 1088-97	8.7	99
182	Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors 2015 ,		3
181	Abstract 4256: High programmed cell death ligand 1 expression and low immune infiltrate score correlate with worse outcome in patients with lung adenocarcinoma 2015 ,		2
180	Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3608-3608	2.2	1
179	Notch1 mutations to define a subgroup of adenoid cystic carcinoma (ACC): Tumor stage, propensity to bone and liver metastasis, risk of relapse, and overall survival.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6081-6081	2.2	3
178	Genomic heterogeneity of lung cancers and its potential clinical implications.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7530-7530	2.2	
177	Association of epithelial-mesenchymal transition with an immunosuppressive, inflammatory tumor microenvironment with elevated levels of checkpoint inhibitors in lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3030-3030	2.2	
176	Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer. <i>Scientific Reports</i> , 2014 , 4, 4480	4.9	37
175	Enhanced PI3K p110 β signaling confers acquired lapatinib resistance that can be effectively reversed by a p110 β selective PI3K inhibitor. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 60-70	6.1	31
174	An integrin β KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. <i>Nature Cell Biology</i> , 2014 , 16, 457-68	23.4	257

173	Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. <i>Cancer Research</i> , 2014 , 74, 2731-41	10.1	32
172	HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. <i>Head and Neck</i> , 2014 , 36, 1547-54	4.2	26
171	Realizing the potential of plasma genotyping in an age of genotype-directed therapies. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	38
170	Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. <i>Cancer Immunology Research</i> , 2014 , 2, 831-8	12.5	226
169	Endothelial progenitor cell mobilization by preoperative exercise: a bone marrow response associated with postoperative outcome. <i>British Journal of Anaesthesia</i> , 2014 , 113, 652-60	5.4	10
168	Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	74
167	Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, 850-7	4	49
166	Comprehensive molecular profiling of lung adenocarcinoma. <i>Nature</i> , 2014 , 511, 543-50	50.4	3310
165	A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2738-50	6.1	62
164	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. <i>Science</i> , 2014 , 346, 256-9	33.3	659
163	Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemo-naïve patients with unresectable malignant pleural mesothelioma. <i>Clinical Lung Cancer</i> , 2014 , 15, 197-201	4.9	24
162	A pan-cancer proteomic perspective on The Cancer Genome Atlas. <i>Nature Communications</i> , 2014 , 5, 3887	17.4	324
161	Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy 2014 , 505-526		
160	EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. <i>Annals of Oncology</i> , 2014 , 25, 1941-1948	10.3	15
159	Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. <i>BMC Genomics</i> , 2014 , 15, 1079	4.5	37
158	Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors. <i>European Journal of Cancer</i> , 2014 , 50, 7	7.5	3
157	Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. <i>Molecular Therapy</i> , 2014 , 22, 1494-1503	11.7	142
156	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. <i>Nature Communications</i> , 2014 , 5, 5241	17.4	573

155	A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 965-973	8.9	25
154	Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 675-84	8.9	18
153	About CD45-/CD31+/CD105+ circulating cells in patients with gynecologic malignancies--letter. <i>Clinical Cancer Research</i> , 2014 , 20, 1393	12.9	
152	VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 3849-61	12.9	36
151	Quantitative evaluation of drug-induced microvascular constriction in mice kidney using a novel tool for 3D geometrical analysis of ex vivo organ vasculature. <i>Toxicologic Pathology</i> , 2014 , 42, 774-83	2.1	6
150	Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3018-3018	2.2	2
149	The KRAS-variant and treatment response in BATTLE-1.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8135-8135	2.2	3
148	Intratumor heterogeneity (ITH) of lung adenocarcinomas defined by multiregion whole exome sequencing (WES).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11032-11032	2.2	
147	Il-8 as an underutilized prognostic factor in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 409-409	2.2	
146	Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. <i>Cancer</i> , 2013 , 119, 1768-75	6.4	37
145	Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. <i>Targeted Oncology</i> , 2013 , 8, 117-25	5	6
144	High Throughput Clonogenic Survival Screen Identifies Novel Radiation Sensitizers for K-ras Mutant Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 87, S651	4	2
143	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. <i>Clinical Cancer Research</i> , 2013 , 19, 279-90	12.9	649
142	CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. <i>Cancer Research</i> , 2013 , 73, 571-82	10.1	114
141	Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 6322-8	12.9	144
140	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 895-902	2.2	310
139	Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. <i>Cancer Discovery</i> , 2013 , 3, 870-9	24.4	93
138	Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. <i>Clinical Cancer Research</i> , 2013 , 19, 6967-75	12.9	49

137	Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 658-61	8.9	14
136	Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 222-8	8.9	72
135	Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1519-28	8.9	18
134	Small-cell lung cancer: treatment of extensive-stage disease 2013 , 142-158		
133	TGF β Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. <i>PLoS ONE</i> , 2013 , 8, e65659	3.7	14
132	The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. <i>PLoS ONE</i> , 2013 , 8, e77117	3.7	84
131	KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. <i>Journal of Clinical Investigation</i> , 2013 , 123, 5231-46	15.9	130
130	BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS8118-TPS8118	11.8	4
129	Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. <i>Oncotarget</i> , 2013 , 4, 772-84	3.3	15
128	Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. <i>Biochemical Pharmacology</i> , 2012 , 83, 1456-64	6	30
127	Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. <i>Neuro-Oncology</i> , 2012 , 14, 1379-92	1	161
126	Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, e61-7	4	77
125	Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 441-4	2.2	87
124	Sorafenib in non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 1417-26	5.9	20
123	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. <i>Lancet Oncology</i> , 2012 , 13, 827-37	21.7	212
122	Comprehensive genomic characterization of squamous cell lung cancers. <i>Nature</i> , 2012 , 489, 519-25	50.4	2820
121	Circulating Biomarkers of Response to Sunitinib in Gastroenteropancreatic Neuroendocrine Tumors. <i>Molecular Diagnosis and Therapy</i> , 2012 , 16, 151-161	4.5	12
120	Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. <i>PLoS ONE</i> , 2012 , 7, e31087	3.7	30

119	Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. <i>PLoS ONE</i> , 2012 , 7, e36116	3.7	70
118	A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2012 , 23, 46-52	10.3	99
117	Circulating biomarkers in advanced renal cell carcinoma: clinical applications. <i>Current Oncology Reports</i> , 2012 , 14, 221-9	6.3	24
116	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 228-39	9.7	331
115	Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2021-32	6.1	39
114	Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. <i>Cancer Discovery</i> , 2012 , 2, 798-811	24.4	323
113	The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. <i>Cancer Research</i> , 2012 , 72, 2275-84	10.1	88
112	C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1211-7	8.9	37
111	Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. <i>Molecular Diagnosis and Therapy</i> , 2012 , 16, 151-61	4.5	5
110	Plasma cytokines and angiogenic factors (CAFs) associated with risk of recurrence and tumor dependence in patients (pts) with nonmetastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 383-383	2.2	
109	Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. <i>British Journal of Cancer</i> , 2011 , 105, 112-7	8.7	21
108	Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. <i>Clinical Cancer Research</i> , 2011 , 17, 6130-9	12.9	225
107	1404 POSTER DISCUSSION Baseline (BL) IL-6, IL-8, and VEGF as Predictive and Prognostic Markers for Overall Survival (OS) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts) Treated in a Phase III Trial of Pazopanib (PAZO) Versus Placebo (PL). <i>European Journal of Cancer</i> , 2011 , 47, S170	7.5	5
106	Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. <i>Lancet Oncology</i> , 2011 , 12, 1109-17	21.7	78
105	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1313-28	15.9	124
104	Mesothelioma and small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, S1825-6	8.9	1
103	The BATTLE trial: personalizing therapy for lung cancer. <i>Cancer Discovery</i> , 2011 , 1, 44-53	24.4	660
102	Targeted therapies for lung cancer: clinical experience and novel agents. <i>Cancer Journal (Sudbury, Mass)</i> , 2011 , 17, 512-27	2.2	80

101	Effect of low-fat diets on plasma levels of NF- κ B-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. <i>Cancer Prevention Research</i> , 2011 , 4, 1590-8	3.2	38
100	Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 5705-14	12.9	121
99	miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. <i>Molecular Cancer Research</i> , 2011 , 9, 25-35	6.6	148
98	Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. <i>Clinical Cancer Research</i> , 2011 , 17, 4872-81	12.9	50
97	Vandetanib restores head and neck squamous cell carcinoma cells sensitivity to cisplatin and radiation in vivo and in vitro. <i>Clinical Cancer Research</i> , 2011 , 17, 1815-27	12.9	64
96	DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. <i>Clinical Cancer Research</i> , 2011 , 17, 2035-43	12.9	74
95	Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. <i>Cancer Research</i> , 2011 , 71, 5512-21	10.1	48
94	Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. <i>British Journal of Cancer</i> , 2011 , 105, 382-92	8.7	45
93	Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4079-4079	2.2	4
92	Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 401-401	2.2	1
91	Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. <i>Oncogene</i> , 2010 , 29, 2616-27	9.2	66
90	Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. <i>Oncogene</i> , 2010 , 29, 2938-49	9.2	62
89	Blasted cell line names. <i>Cancer Informatics</i> , 2010 , 9, 251-5	2.4	
88	Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. <i>Journal of Clinical Oncology</i> , 2010 , 28, 453-9	2.2	383
87	Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. <i>Cancer Research</i> , 2010 , 70, 2171-9	10.1	106
86	. <i>Clinical Cancer Research</i> , 2010 , 16, 1341-1341	12.9	
85	Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 1755-63	6.1	40
84	Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. <i>Cancer Research</i> , 2010 , 70, 6477-85	10.1	49

83	Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 193-201	2.2	123
82	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2010 , 11, 619-26	21.7	364
81	Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1894-904	8.9	50
80	A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. <i>Cancer</i> , 2010 , 116, 1751-6	6.4	60
79	A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid. <i>Cancer</i> , 2010 , 116, 2465-75	6.4	18
78	Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3042-3042	2.2	4
77	Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. <i>Cancer Research</i> , 2009 , 69, 1836-43	10.1	49
76	Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 3600-9	12.9	81
75	Quantification of Circulating Endothelial Cells by Flow Cytometry. <i>Clinical Cancer Research</i> , 2009 , 15, 3640.2-3640	12.9	1
74	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. <i>Clinical Cancer Research</i> , 2009 , 15, 3484-94	12.9	244
73	Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 6852-61	12.9	84
72	14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. <i>Cancer Cell</i> , 2009 , 16, 195-207	24.3	167
71	Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. <i>Cancer</i> , 2009 , 115, 2346-54	6.4	22
70	Molecular targets for cancer chemoprevention. <i>Nature Reviews Drug Discovery</i> , 2009 , 8, 213-25	64.1	113
69	Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. <i>Clinical Cancer Research</i> , 2009 , 15, 267-73	12.9	140
68	Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL-6, and IL-8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib 2009 ,		6
67	HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2009 , 119, 2160-70	15.9	115
66	HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2009 , 119, 3182-3182	15.9	4

65	Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib. <i>Journal of Surgical Research</i> , 2008 , 149, 115-9	2.5	24
64	Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. <i>Microvascular Research</i> , 2008 , 76, 15-22	3.7	42
63	Lung cancer. <i>New England Journal of Medicine</i> , 2008 , 359, 1367-80	59.2	1920
62	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5407-15	2.2	198
61	Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. <i>Cell Cycle</i> , 2008 , 7, 3747-58	4.7	51
60	Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. <i>Clinical Cancer Research</i> , 2008 , 14, 2785-95	12.9	32
59	Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 418-24	6.1	38
58	Second-line treatment of advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 430-40	8.9	52
57	The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. <i>Journal of Thoracic Oncology</i> , 2008 , 3, S131-4	8.9	32
56	Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. <i>Journal of Thoracic Oncology</i> , 2008 , 3, S107-12	8.9	13
55	Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. <i>Journal of Cellular Physiology</i> , 2008 , 216, 698-707	7	29
54	Dr. Folkman's legacy-a life of angiogenesis research. <i>Apmis</i> , 2008 , 116, 89-92	3.4	
53	A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5093-5093	2.2	4
52	Circulating endothelial cells are a potential biomarker for patients with renal cell carcinoma (RCC) with and without von Hippel Lindau (VHL) syndrome. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5098-5098	2.2	2
51	Profiling of cytokines and angiogenic factors (C/AF) in head and neck (HN) cancer correlates circulating biomarkers with clinical outcomes following induction chemotherapy. <i>Journal of Clinical Oncology</i> , 2008 , 26, 6005-6005	2.2	2
50	Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC. <i>Journal of Clinical Oncology</i> , 2008 , 26, 8009-8009	2.2	2
49	Angiogenesis Inhibitors for the Treatment of Lung Cancer 2008 , 409-426		0
48	Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 239-49	5.9	112

47	Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4270-7	2.2	254
46	Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2007 , 8 Suppl 2, S79-85	4.9	55
45	Metronomic chemotherapy enhances the efficacy of antivasular therapy in ovarian cancer. <i>Cancer Research</i> , 2007 , 67, 281-8	10.1	124
44	PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. <i>Cancer Research</i> , 2007 , 67, 11924-32	10.1	589
43	Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. <i>Clinical Cancer Research</i> , 2007 , 13, 2643-50	12.9	189
42	Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4952-60	2.2	214
41	Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 236-241	0.4	
40	The convergent development of molecular-targeted drugs for cancer treatment and prevention. <i>Clinical Cancer Research</i> , 2007 , 13, 4035-41	12.9	32
39	Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, s4617-22	12.9	39
38	Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007 , 292, L742-7	5.8	55
37	M10-01: Molecular pathogenesis of lung cancer with translation to the clinic. <i>Journal of Thoracic Oncology</i> , 2007 , 2, S178-S179	8.9	5
36	Endothelial progenitor cells contribute to accelerated liver regeneration. <i>Journal of Pediatric Surgery</i> , 2007 , 42, 1190-8	2.6	41
35	Emerging antiangiogenic agents in lung cancer. <i>Clinical Lung Cancer</i> , 2006 , 7, 304-8	4.9	18
34	Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 4441s-4445s	12.9	74
33	Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3555-61	2.2	165
32	Vascular Endothelial Growth Factor (VEGF) Pathway. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 768-770	8.9	26
31	Vascular Endothelial Growth Factor (VEGF) Pathway. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 768-770	8.9	26
30	Angiogenesis inhibitors for lung cancer: clinical developments and future directions. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 744-8	8.9	7

29	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. <i>Journal of Clinical Investigation</i> , 2006 , 116, 2695-706	15.9	372
28	Vascular endothelial growth factor (VEGF) pathway. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 768-70	8.9	18
27	O-100 ZD6474 plus docetaxel in patients with previously treated NSCLC: Results of a randomized, placebo-controlled Phase II trial. <i>Lung Cancer</i> , 2005 , 49, S35-S36	5.9	22
26	Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. <i>Clinical Cancer Research</i> , 2005 , 11, 3514-22	12.9	138
25	Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. <i>Cancer Research</i> , 2005 , 65, 11044-50	10.1	108
24	ZD6474--clinical experience to date. <i>British Journal of Cancer</i> , 2005 , 92 Suppl 1, S14-20	8.7	55
23	A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3023-3023	2.2	23
22	A phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4120-4120	2.2	7
21	Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9036-9036	2.2	10
20	Tumor Angiogenesis: General Principles and Therapeutic Approaches 2005 , 41-55		
19	Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. <i>Clinical Cancer Research</i> , 2005 , 11, 678-89	12.9	27
18	Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. <i>Annals of Oncology</i> , 2004 , 15, 1187-93	10.3	73
17	Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. <i>Clinical Cancer Research</i> , 2004 , 10, 5732-40	12.9	89
16	Farnesyl transferase inhibitors for patients with lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 4254s-4257s	12.9	38
15	ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3051-3051	2.2	7
14	Angiogenesis inhibitors and hypoxia. <i>Nature Medicine</i> , 2003 , 9, 1104; author reply 1104-5	50.5	25
13	Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. <i>Cancer Research</i> , 2003 , 63, 8345-50	10.1	73
12	Angiogenesis and antiangiogenic approaches to sarcomas. <i>Current Opinion in Oncology</i> , 2001 , 13, 261-9	4.2	29

11	Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain. <i>Neuroscience</i> , 1999 , 90, 815-21	3.9	78
10	Subcellular localization of epitope-tagged neurotrophins in neuroendocrine cells. <i>Journal of Neuroscience Research</i> , 1998 , 51, 463-72	4.4	56
9	Neurotrophins induce release of neurotrophins by the regulated secretory pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 9614-9	11.5	109
8	The role of the nerve growth factor carboxyl terminus in receptor binding and conformational stability. <i>Journal of Biological Chemistry</i> , 1997 , 272, 29222-8	5.4	18
7	The regulated secretion and vectorial targeting of neurotrophins in neuroendocrine and epithelial cells. <i>Journal of Biological Chemistry</i> , 1996 , 271, 25430-7	5.4	80
6	The biosynthesis of neurotrophin heterodimers by transfected mammalian cells. <i>Journal of Biological Chemistry</i> , 1995 , 270, 12297-304	5.4	53
5	Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF.. <i>EMBO Journal</i> , 1991 , 10, 2395-2400	13	104
4	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features		2
3	Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing		1
2	Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells		1
1	Deep learning-based prediction of the T cell receptor-antigen binding specificity. <i>Nature Machine Intelligence</i> ,	22.5	9